Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters








Language
Year range
1.
Cancer Research and Clinic ; (6): 38-41, 2021.
Article in Chinese | WPRIM | ID: wpr-886003

ABSTRACT

Objective:To observe the changes of serum progastrin-releasing peptide (Pro-GRP) and neuron specific enolase (NSE) levels in patients with small cell lung cancer (SCLC) in the concurrent chemoradiotherapy and their significances.Methods:The data of 80 patients with SCLC who were admitted to Shanxi Provincial Cancer Hospital from June 2018 to December 2019 were retrospectively analyzed, and the patients were divided into the concurrent chemoradiotherapy group (26 cases) and chemotherapy alone group (54 cases). Enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence method were used to detect serum Pro-GRP and NSE levels before and after treatment; and the association of Pro-GRP and NSE levels with patients' condition, treatment method, treatment stage and treatment efficacy was analyzed.Results:Among 80 patients with SCLC, Pro-GRP level of patients with limited-stage [127.43 pg/ml (17.61- 1 547.30 pg/ml)] was lower than that of patients with extensive-stage [547.87 pg/ml (20.20-2 111.00 pg/ml)], and the difference was statistically significant ( U = 312.65, P < 0.01). NSE level of patients with limited-stage [25.02 μg/L (4.72-64.64 μg/L)] was also lower than that of patients with extensive-stage [88.08 μg/L (5.52-104.64 μg/L)], and the difference was statistically significant ( U = 203.14, P < 0.01). The levels of Pro-GRP and NSE in the concurrent chemoradiotherapy group and the chemotherapy alone group were decreased after 2 and 4 cycles of chemotherapy compared with those before treatment, and the differences were statistically significant (all P < 0.01); the decrease range in the concurrent chemoradiotherapy group was more than that in the chemotherapy alone group, but the differences between the two groups were not statistically significant (all P > 0.05). The objective response rate in the concurrent chemoradiotherapy group was 96.15% (25/26), which was higher than that in the chemotherapy alone group [70.37% (38/54)], and the difference was statistically significant ( χ2 = 6.972, P = 0.008). Conclusions:The serum levels of Pro-GRP and NSE for patients with SCLC in the concurrent chemoradiotherapy can reflect the changes of the condition of SCLC patients. Concurrent chemoradiotherapy is more effective compared with the chemotherapy alone in the treatment of SCLC.

2.
Chinese Journal of Primary Medicine and Pharmacy ; (12): 1106-1110, 2020.
Article in Chinese | WPRIM | ID: wpr-866395

ABSTRACT

Objective:To analyze the clinical effect, adverse events and prognosis of microwave hyperthermia combined with radiotherapy in the treatment of patients with advanced gastric cancer.Methods:From May 2017 to May 2019, 80 patients with advanced gastric cancer admitted to Cancer Hospital of Shanxi Province were selected and divided into two groups according to the random digital table method, with 40 cases in each group.The control group was treated with radiotherapy, and the study group was treated with microwave hyperthermia on the basis of the control group.The clinical efficacy, adverse events and prognosis of the two groups were compared.Results:The total effective rate in the study group was 90.00%(36/40), which was higher than 70.00%(28/40) in the control group (χ 2=5.000, P<0.05). After treatment, the diameter of tumor in the study group was lower than that in the control group[(2.30±0.20)cm vs.(2.66±0.23)cm, t=7.470, P<0.05]. The incidence of adverse events in the study group was 10.00%(4/40), which was lower than 27.50%(11/40) in the control group(χ 2=4.020, P<0.05). The quality of life scores of the study group[physiological function (74.17±5.23)points, physical pain (73.07±5.49)points, general health (75.13±5.50)points, mental state (75.16±3.27)points and social function (75.49±3.24)points] were better than those of the control group[(62.55±5.70)points, (63.24±6.37)points, (65.72±5.30)points, (63.05±2.49)points, (65.34±4.59)points]( t=9.500, 7.393, 7.791, 18.634, 11.425, all P<0.05). Conclusion:Microwave hyperthermia combined with radiotherapy can reduce adverse events and improve the quality of life of patients with advanced gastric cancer.

3.
Cancer Research and Clinic ; (6): 860-863,870, 2018.
Article in Chinese | WPRIM | ID: wpr-735165

ABSTRACT

Objective To compare the efficacy and toxicity of paclitaxel and carboplatin regimen concurrent chemoradiotherapy and radiotherapy alone in the treatment of stage Ⅲ cervical cancer.Methods A retrospective analysis of 158 patients with stage Ⅲ cervical cancer who were admitted to Shanxi Provincial Cancer Hospital from May 2009 to October 2012 was conducted.According to different treatment methods,86 patients were in the concurrent chemoradiotherapy group and 72 patients were in the radiotherapy group.The efficacy and adverse reactions of the two groups were compared.Results The effective rate (complete remission + partial remission) in the concurrent radiotherapy group and radiotherapy group was 95.3% (82/86) and 84.7 % (61/72),respectively,and the difference was statistically significant (x2 =5.15,P =0.023).The 1-,2-,3-,and 5-year survival rates of the concurrent radiotherapy group and radiotherapy group were 93.0 % (80/86),77.9 % (67/86),68.6 % (59/86),60.5 % (52/86),and 81.9 % (59/72),61.1% (44/72),41.7 % (30/72),36.1% (26/72),respectively,and the differences were statistically significant (x2 values were 4.55,5.29,11.56,9.30,all P < 0.05).The short-term adverse reactions in the concurrent chemoradiotherapy group and radiotherapy group were mainly myelosuppression and gastrointestinal reactions,and the incidence of myelosuppression was 87.2 % (75/86) and 50.0 % (36/72),respectively,and the difference was statistically significant (x2 =25.96,P < 0.01);the incidence of gastrointestinal reactions was 91.9 % (79/86) and 20.8 % (15/72),respectively,and the difference was statistically significant (x2 =82.04,P < 0.01).The incidence of radiation proctitis in the concurrent radiotherapy and chemotherapy group was 17.4 % (15/86) and 16.7 % (12/72),respectively,and the difference was not statistically significant (x2 =0.017,P =0.89);the incidence of radiation cystitis was 7.0 % (6/86) and 5.6 % (4/72),respectively,and the difference was not statistically significant (x2 =0.134,P =0.71).Conclusion Paclitaxel and carboplatin regimen chemotherapy combined with radiotherapy can improve the survival rate of patients with stage Ⅲ cervical cancer,and the adverse reactions are tolerable.

4.
Cancer Research and Clinic ; (6): 306-307,311, 2010.
Article in Chinese | WPRIM | ID: wpr-596781

ABSTRACT

Objective To observe the clinical pathological changes lower rectal carcinoma after preoperative radiation.Methods Thirty cases of rectal carcinoma underwent preoperative radiotherapy at a dose of 30 Gy.Gross size of the tumors was measured and histological changes were analyzed before and after radiation.Results The rates of complete regression,partial regression and no response to radiation of the tumors were 23.3%.53.3%and 23.3%.Significant tumor regression RCRG Ⅲ wag seen in 6 cages (20.0%) after radiotherapy.while partially tumor regression RCRG Ⅱ was seen in 15 cases (50.0%). Conclusion Preoperative radiation at a dose of 30 Gy on lower rectal carcinoma induces degeneration and necrosis of the tumor cells with complete or partial regression in most cases.Necrosis,fibrosis and thickening of vascular intima in the rectal cancer tissue after radiotherapy is more frequent than those without radiotherapy.It may be the potential reason for increased resection rate and sphincter saving after radiotherapy. It hag a great significance for sphincter-preservation surgery in this group of rectal carcinomas.

5.
Cancer Research and Clinic ; (6): 47-48, 2009.
Article in Chinese | WPRIM | ID: wpr-381346

ABSTRACT

Objective To evaluate the short-term clinical effect of 125Ⅰ seeds interstitial braehytherapy for recurrent malignant tumor after radiotherapy. Methods 21 patients with recurrent gynecologic tumors after radiotherapy received 125Ⅰ seeds interstitial braehytherapy through TPS, ultrasound. 125Ⅰ seeds radiotherapy per grain was for 20.72-29.60 MBq. The distribution of seeds was checked by X-my after treatment. The clinical therapeutic efficacy was observed by chest CT, ultrasound. Results The overall effective rate was 100 %, CR 85.71%(18/21), PR 14.29 %(3/21). Conclusion 125Ⅰ seeds interstitial brachytherapy is minimally invasive, convenient, safe, utility and feasible in clinical practice. The radioactive protection is easy. It is a new and high technology of malignant tumor treatment. Colligation treatment method is increased by this technique. But this technology cannot replace routine method.

SELECTION OF CITATIONS
SEARCH DETAIL